Objectives: To test whether or not one of two biological mediators (recombinant human bone morphogenetic protein-2 (rhBMP-2) and recombinant human platelet-derived growth factor (rhPDGF-BB)) is superior to the other and compared with control groups for bone regeneration around implants based on histomorphometrical outcome measures.
groups with biological mediators (DBBM/BMP-2 = 13.35%; DBBM/PDGF = 6.96%) and only slightly increased in group DBBM (10.68%) and the control group (4.95%) compared with 8 weeks. The first bone-to-implant contact values on the buccal side were minimal for DBBM/BMP-2 (0.57 mm) and maximal for control (3.72 mm) at 8 weeks.
Conclusions: The use of biological mediators (rhBMP-2 and rhPDGF-BB) can increase the amount of bone regeneration at dehiscence-type defects compared with controls at 8 weeks, but not at 16 weeks due to enhanced hard tissue remodeling processes.
Guided bone regeneration (GBR) procedures are routinely performed in dental practice to regenerate missing hard and soft tissue volume prior to or simultaneously with dental implant placement (H€ ammerle et al. 2002; Bornstein et al. 2008) . For that purpose, autogenous bone or bone substitute materials in combination with non-resorbable barrier membranes are used. These membranes offer advantages in terms of the stability of the augmented site and render high clinical success rates (von Arx et al. 2001; Friedmann et al. 2001; Buser et al. 2002) . However, clinical disadvantages include an additional surgical procedure to remove the membrane and increased rates of membrane exposure (Becker et al. 1994; Simion et al. 1994; Strietzel 2001) . In order to overcome these shortcomings, resorbable membranes were introduced. Among these, collagen membranes are well documented and have shown to render high success rates (Pitaru et al. 1987; Zitzmann et al. 1997 Zitzmann et al. , 2001 Hockers et al. 1999; Friedmann et al. 2001) . However, these relatively soft membranes do not maintain space per se and a compression of the regenerated site can potentially result in a displacement of
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More recently, bone regeneration was performed by applying the principles of tissue engineering (Gothard et al. 2014) , focused on the investigation of bioactive molecules to induce local bone formation. Based on a number of systematic reviews, the most promising factors for localized ridge augmentation include recombinant human bone morphogenetic protein-2 (rhBMP-2) and recombinant platelet-derived growth factor (rhPDGF-BB) (Jung et al. 2008; Fisher et al. 2013; Khojasteh et al. 2013) .
RhBMP-2 promotes better results on ridge regeneration following socket grafting and bone regeneration and osseointegration around dental implants (Jung et al. 2003 (Jung et al. , 2009 Kim et al. 2015) . RhPDGF-BB has been employed in the field of periodontology in combination with various carrier materials for the treatment of infrabony defects (Nevins et al. 2005 (Nevins et al. , 2013 Jayakumar et al. 2011; Thakare & Deo 2012; Khoshkam et al. 2015) . In implant dentistry, rhPDGF-BB has been used to enhance bone formation in localized bone defects and for vertical ridge augmentation (Simion et al. 2006 (Simion et al. , 2007 Nevins et al. 2009 Nevins et al. , 2012 McAllister et al. 2010; Thoma et al. 2012; Xu et al. 2016) .
Whereas both rhBMP-2 and rhPDGF-BB have been successfully used in various animal models and clinical applications (Boyan et al. 2000; Cochran et al. 2000; Jung et al. 2003; Simion et al. 2006; Thoma et al. 2010; Darby & Morris 2013) , no data can be retrieved from the literature comparing the two biological mediators for guided bone regeneration around dental implants in the same experimental model. Therefore, the aims of the study were to test whether or not one of two biological mediators (rhPDGF-BB or rhBMP-2) is superior to the other and compared with control groups for bone regeneration around implants based on histological and histomorphometrical outcome measures.
Material and methods
The study was designed as a randomized experimental study employing 10 healthy adult beagle dogs (weight = 15 kg). The animals were kept in a purpose-designed room for experimental animals and were fed a standard laboratory diet. The study was approved by the Institutional Animal Care and Use Committee of Yonsei Medical Center, Seoul, Korea (permission no.: 2013-0317).
All the materials used in this study are commercially available. Preparation of rhBMP-2 (Cowellmedi, Busan, Republic of Korea) was similar to a previous report . RhPDGF-BB (GEM 21S â , Osteohealth, BioMimetic Therapeutics Inc, Shirley, NY, USA) was purchased from the manufacturer.
Surgical procedure
The surgical procedure has been described in the previous report . In brief, all surgical procedures were performed under general anesthesia. Subsequently, local infiltration anesthesia was additionally injected at the surgical site.
Surgery 1
After mucoperiosteal flaps were reflected bilaterally in the mandible, the third and fourth premolar as well as the first molar (P3, P4, M1) were carefully removed. Primary wound closure was obtained using monofilament sutures (Monosyn
Braun Tuttlingen, Germany). Additional medications were administrated after the surgeries, including an antibiotic prophylaxis (Moxicle, Daewoong Pharm., Gyeonggi-do, Korea), an antiinflammatory and an analgesic drug (Ketorolac, Hana Pharm., Gyeonggi-do, Korea; Meloxicam, Boehringer Ingelheim, Bogota D.C., Colombia) for 7 days.
Surgery 2
After three months of healing, defect preparation, implant placement and GBR procedures were performed in all dogs. Following a midcrestal incision, mucoperiosteal flaps were reflected to expose the buccal and lingual alveolar plate. A vertical releasing incision was placed distal to the canine. All granulation tissue was carefully removed and the edentulous ridge was flattened to obtain a width of at least 7 mm. Two implant sites were prepared bilaterally under abundant irrigation with sterile saline, at a distance of 14 mm apart and at the same distance from the buccal cortical bone plate. Following implant site preparation, two standardized box-shaped defects (mesiodistal width: 10 mm, depth: 5 mm, height: 5 mm) were prepared bilaterally at the buccal aspect of the mandibular alveolar ridge (Fig. 1a,b) . The defect sites were standardized using a periodontal probe and rinsed with sterile saline to completely remove any residual debris. Thereafter, screw-type titanium implants (length 8 mm, diameter 4.0 mm, Astra Tech, OsseoSpeedTM TX 4.0 S, DENTSPLY Implants, M€ olndal, Sweden) were inserted with good primary stability in a way that the implant shoulder coincided with the bone crest at the lingual aspect. Titanium closure screws were applied.
The buccal dehiscence-type defects were allocated based on a computer software-generated randomization list and the use of sealed envelopes. The treatment modalities were applied: iii DBBM group: DBBM + CM. iv Control group: no treatment.
At the sites allocated for the use of bone substitutes, the defects were filled with a standardized amount of biomaterial (DBBM). For the DBBM/BMP-2 and DBBM/PDGF groups, 0.1 ml of rhBMP-2 (Cowellmedi, Busan, Korea) or rhPDGF-BB (GEM 21S â , Osteohealth, BioMimetic Therapeutics Inc) at a concentration of 0.3 mg/ml was loaded onto 0.07 g of DBBM granules (BioOss â , Geistlich Biomaterials, Wolhusen, Switzerland), respectively. Three minutes of binding time was provided for both groups. For the DBBM group, 0.1 ml of saline was mixed with DBBM. The DBBM biomaterial was covered with a CM in order extending 2 mm beyond the defect margins ( Fig. 1c-e) . Before applying the membrane, the horizontal defect extensions were measured from the buccal implant surface to the most buccal aspect of the graft material. Bleeding was allowed to form a blood clot in empty sites, where no further treatment was applied. Resorbable polylactide pins (Inion CPS, Inion Ltd, Tampere, Finland) were inserted apically at all the sites in order to stabilize the membranes.
Following periosteal-releasing incisions, the mucoperiosteal flaps were advanced coronally and primary wound closure was achieved by placing horizontal mattress sutures and interrupted sutures (4-0 Monosyn Glyconate Monofilament; B. Braun, Tuttlingen, Germany). The sutures were removed 14 days after surgery 2.
After a healing period of 2 months (n = 5) and 4 months (n = 5), the animals were terminated by an overdose of potassium chloride 3 g (Daihan Potassium chloride-40, Daihan pharm., Ansan, Korea). The jaws were dissected, and blocks containing the experimental specimens with intact soft tissues were obtained.
Histological preparation
The specimens were fixed in 10% formalin for 2 weeks. An EXAKT cutting system (EXAKT â Apparatebau, Norderstedt, Germany) was used to cut the specimens at the center of the implant in a mesiodistal direction. The specimens were dehydrated in an ascending series of alcohol and subsequently embedded in methacrylate-based resin, polymerized and then fixed to the vacuum head of the EXAKT macrocutter. The thickness of sections was made with approximately 100 lm and then ground and polished on the EXAKT microgrinder to a thickness of 15 lm. Paragon was used to stain the microscope slides.
Histomorphometrical analysis
Computer-assisted histomorphometrical measurements were obtained using an automated image analysis system (LAS V4.3, Leica Microsystems, Wetzlar, Germany), coupled with a photograph camera (Leica DFC450, Leica Microsystems, Wetzlar, Germany) mounted on a light microscope (Leica DM6000 B, Leica Microsystems).
In the central sections, the region of interest (ROI) was determined (Fig. 2a) v The first bone-to-implant contact (mm; fBIC), measured from the implant shoulder to the first bone-to-implant contact on the buccal (fBIC b ) and lingual (fBIC l ) sides.
Statistical analysis
The metric variables were described with mean, median, standard deviation and quartiles. The comparisons of the four group means for the metric variables were made using mixed linear models as the data within a dog were dependent (clustered). The dog was set as random effect in these models. The assumptions of these models were validated also in view of the small sample sizes.
Results
The animals did not present signs of postoperative infections or weight reduction. There were no local complications in surgical areas during the entire study period.
Descriptive histology
All implants were well osseointegrated. In the majority of the sites, the most coronal bone-toimplant contact was close to the implant shoulder on the lingual side. On the buccal side, in a majority of sites, the fBIC was located more apical compared with the lingual side. In all sites, the soft tissues covered the implants, even in cases with implants threads not being covered with mineralized tissue. Within the augmented area, angiogenesis was observed in all groups at 8 and 16 weeks. In empty sites, this revascularization was predominantly close to the implant surface and the apical border of the defect, whereas in all other groups (all with DBBM), newly formed blood vessels surrounded the DBBM particles. A relatively small number of osteoclasts were located at bone and bone substitute surfaces at 8 weeks. This number increased over the next 8 weeks.
In BMP-2 sites, at 8 weeks, the contour was mostly re-established (Fig. 3a) . DBBM particles were completely surrounded by woven and lamellar bone. The mucosa did not show a collapse of the contour. At 16 weeks, the contour changed and presented a loss (Fig. 4a) . Moreover, most of the DBBM particles were not present anymore. Lamellar bone formation was limited, mostly close to the implant surface.
At 8 weeks, in PDGF sites, the contour was mostly re-established with the augmented area being filled with DBBM particles and woven bone (Fig. 3b) . In contrast to DBBM sites, bone formation was not limited to the implant surface, but was also evident surrounding the DBBM particles. At 16 weeks, part of the contour was lost in most cases, and the amount of DBBM particles appeared to be less. Moreover, only limited woven and some lamellar bone was observed (Fig. 4b) .
In DBBM sites, the ridge contour was reestablished in most cases, without obvious differences between the time-points (Figs 3c  and 4c ). Woven bone formation was evident along the implant surface, increasing from 8 to 16 weeks. At 8 weeks, the bone-to-bone substitute contact was very limited, whereas at 16 weeks, new bone formation (woven and lamellar bone) was evident around the DBBM particles.
In empty sites at both time-points (8 and 16 weeks), the ridge contour was not reestablished demonstrating exposed implant threads on roughly 50% of the implant surface (Figs 3d and 4d) . Moreover, in a majority of the sites, the vertical dimension of the 
DBBM/BMP-2 group (a). DBBM/PDGF group (b). DBBM group (c). Control group (d)
. DBBM/BMP-2 = bovine-derived particulated bone mineral (DBBM) mixed with recombinant human bone morphogenetic protein-2 (rhBMP-2) and a collagen membrane (CM); DBBM/PDGF = DBBM mixed with recombinant platelet-derived growth factor (rhPDGF-BB) and CM; DBBM = DBBM and CM; control = empty control. B, native bone; NB, new bone formation; BS, bone substitute material.
bone defect was even larger compared with the originally established defect dimension. Bone formation at the implant surface was not evident. The soft tissues, however, covered all implants, but the mucosa appeared to be collapsed.
Histomorphometrical analysis
All data are presented in Tables 1 and 2 and 5.07% AE 8.91% for control. At 16 weeks, no statistically significant mean differences were observed between the groups (P > 0.05).
The mean amount of regenerated bone was 26.97% AE 12.17% for DBBM/BMP-2, 22.02% AE 19.66% for DBBM/PDFG, 5.03% AE 4.30% for DBBM and 1.25% AE 2.60% for control at 8 weeks. The control and DBBM groups demonstrated statistically significant differences in terms of newly formed bone compared with DBBM/BMP-2 (P = 0.0096 and P = 0.0025, respectively). At 16 weeks, these values were lower in the two groups with biological mediators (DBBM/BMP-2: 13.35% AE 11.54%; DBBM/PDGF: 6.96% AE 9.73%) and only slightly increased in group DBBM (10.68% AE 13.78%) and the control group (4.95% AE 8.69%) compared with 8 weeks. No statistically significant differences were observed at 16 weeks (P > 0.05).
The mean values for residual bone substitute material were similar in all groups at both time-points (P > 0.05). A slight loss, however, was observed comparing the 8-week to the 16-week time-point.
The percentage of mineralized tissue (bone + bone substitute material) ranged between 38.38% AE 13.98% for DBBM/BMP-2 and 1.25% AE 2.60% for control at 8 weeks. The control group demonstrated statistically significantly less mineralized tissue compared with the others groups (P = 0.0009 vs. DBBM/ BMP-2, P = 0.0124 vs. DBBM/PDGF and P = 0.0040 vs. DBBM group). At 16 weeks, the values ranged between 20.91% AE 15.70% for DBBM/BMP-2 and 4.95% AE 8.69% for control.
The fBIC values on the buccal side were minimal for DBBM/BMP-2 (0.57 mm AE 1.07 mm) and maximal for control (3.72 mm AE 2.09 mm) at 8 weeks. The DBBM/BMP-2 group demonstrated a statistically significantly smaller fBIC value compared with the DBBM group (P = 0.0015) and the control group (P = 0.0087). At 16 weeks, no statistically significant differences were observed between the groups (P > 0.05).
Discussion
The present experimental study demonstrated that the use of biological mediators significantly increased the regenerated area at 8 weeks compared with controls. At 16 weeks, however, the use of rhBMP-2 and rhPDGF-BB was not beneficial in terms of bone regeneration compared with the bone substitute material alone (DBBM).
Descriptive histology revealed that the use of biological mediators (rhBMP-2; rhPDGF-BB) affected the regeneration process in a positive way up to 8 weeks.
RhBMP-2 has shown to be beneficial in terms of bone regeneration using a variety of bone substitute materials and for various indications (Thoma et al. 2010; Khojasteh et al. 2013; Khoshkam et al. 2015; Lee et al. 2015) . These findings are supported by a systematic review, showing the highest potential for new bone formation among other biological mediators, especially when rhBMP-2 was used in combination with an appropriate carrier material (Khojasteh et al. 2013 ). RhPDGF-BB was included in a recent systematic review with meta-analysis (Khoshkam et al. 2015) . Based on five included studies evaluating the effects of rhPDGF, significantly more bone formation was demonstrated compared with negative controls or carrier materials alone. This is supported by a further systematic review (Khojasteh et al. 2013) analyzing different types of biological mediators. In three of four studies, an advantage for rhPDGF-BB groups was observed compared with negative controls.
From a clinical point of view, the aim would be to re-establish the ridge contour. For that purpose, the relative augmented area (RA/TDA) was calculated. The results of the present study indicated, at 8 weeks, a significantly better performance for the DBBM/ BMP-2 group compared with the DBBM and control groups. The weakest regeneration was obtained in the negative control group. Over time, between 8 and 16 weeks, a major proportion of the regenerated area in both groups using biological mediators was lost. Similar results with rhBMP-2 were reported in previous studies in dogs showing enhanced bone formation compared with the control group at 8 weeks (Wikesj€ o et al. 2004 ) and at 12 weeks (Jovanovic et al. 2007 ), but no significant differences at 16 weeks were observed (Smeets et al. 2009) . A study using rhPDGF-BB in dogs, on standardized mandibular defects, reported similar results compared with a DBBM/PDGF group with a statistically significant higher mean augmented area compared with control sites at an early time-point (3 weeks) (Schwarz et al. 2009 ).
The amount of regenerated bone and the extent of bone formation along the implant surface represent useful parameters to qualitatively assess the regenerated area. At 8 weeks, significantly more bone formation was observed for DBBM/BMP-2 compared with DBBM and the negative control groups, but not the DBBM/PDGF group. In line with a major loss of volume over time, both groups with biological mediators revealed an extensive reduction in the amount of regenerated bone in order of 50.5% for the DBBM/BMP-2 group and 68.4% for the DBBM/PDGF group between 8 and 16 weeks. These outcomes are lined up with the reduction in mineralized tissue and bone substitute material. There was a decrease in mineralized tissue (45.5% for DBBM/BMP-2, 56.8% for DBBM/PDGF and 3.2% for DBBM) and bone substitute material (33.7% for DBBM/BMP-2, 35.9% for DBBM/PDGF and 43.2% for DBBM) in augmented groups between 8 and 16 weeks. This generalized loss could be due to the lack of a more stable and durable membrane. Previous study demonstrated that the carrier material plays a crucial role (Sigurdsson et al. 1996) . In case non-spacemaintaining collagen sponges are used, bone regeneration using rhBMP-2 is limited (Barboza et al. 2000) .
The fBICb showed more favorable results for the DBBM/BMP-2 group, with statistically significant differences compared with the DBBM and control groups. No differences were observed between the others groups. At 16 weeks, the groups with biological mediators lost a considerable amount of bone, and the DBBM and control groups continued to improve the bone formation, resulting in no statistically significant differences. These outcomes corroborate with the relative augmented area (RA/TDA), regenerated bone and mineralized tissue results, where the new bone formation was faster on sites exposed to biological mediators, especially with rhBMP-2. At 16 weeks, no positive effect for the use of biological mediators was observed. For DBBM/BMP-2, this could be explained by the short biological half-life, localized action and rapid local clearance (Kokubo et al. 2003) . Clinically it is important to emphasize that the differences between DBBM/BMP-2 and the other groups were at least 1 mm for fBIC, or 20% of the total defect height. This difference, although not statistically significant, might have a clinical relevance. The fBIC values for the DBBM/BMP-2 group were in line with previous publications (Thoma et al. 2010; Yamashita et al. 2010 ) using rhBMP-2 and smaller compared with the control groups.
The way rhBMP-2 and rhPDGF-BB interact with the surrounding tissues is substantially different. Both factors can act locally, but may also act systemically to affect the growth and function of distant cells and tissues.
RhPDGF-BB is the so-called proliferation factor mainly having a mitogenic function, thereby increasing the number of cells in the area. In contrast, rhBMP-2 is differentiated and primarily responsible for the maturation of cells. The specific function of the two biological mediators may at least in part explain the obtained data in the present study. At the earlier time-point, the overall response in terms of bone regeneration was stronger for rhBMP-2 compared with rhPDGF-BB and probably owing to a strong induction of osteoblast differentiation. RhPDGF-BB, however, did improve the outcomes in terms of bone regeneration compared with the bone substitute material alone, probably due to its function of being mitogenic and enhancing angiogenesis.
Conclusions
Within the limitations of the present experimental study, the use of biological mediators (rhBMP-2 and rhPDGF-BB) can increase the amount of bone regeneration at dehiscencetype defects compared with controls at 8 weeks. The augmented area may undergo enhanced hard tissue remodeling processes during further healing preventing any clinical benefit for the use of biological mediators compared with control groups at a later time-point. 
